Nurix Therapeutics (NRIX) Cash from Operations Growth (3y) (2022 - 2026)

Nurix Therapeutics (NRIX) Cash from Operations Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Nurix Therapeutics 2.64 Bn 2.19 Bn - -73.57%

Historic Data

Download Data
DateValue
May 31, 2026 -73.57%
Feb 28, 2026 -14.07%
Nov 30, 2025 -21.35%
Aug 31, 2025 -7.41%
May 31, 2025 -24.27%
Feb 28, 2025 -12.74%
Nov 30, 2024 -16.40%
Aug 31, 2024 -12.06%
May 31, 2024 -7.98%
Feb 29, 2024 -93.18%
Nov 30, 2023 48.93%
Aug 31, 2023 -88.50%
May 31, 2023 -8.58%
Feb 28, 2023 -47.09%
Nov 30, 2022 -43.86%